Skip to Main Content

Rise and shine, everyone, another busy day is on the way. Although the days may seem to blur together, we can tell there is much to do as our calendar for all sorts of calls gets crowded and reading material piles up. And in times like these, busy is a good thing, yes? To keep the neurons working, we are firing up the coffee kettle for another cup of stimulation. Caramel vanilla cream is the choice today. Please feel free to join us. Meanwhile, here are a few items of interest. Hope your day is successful and safe. …

Seeking to blunt concerns about access to its remdesivir treatment for Covid-19, Gilead Sciences (GILD) signed deals with five generic companies in India and Pakistan to manufacture and distribute the experimental medicine to 127 countries, STAT says. Under the agreements, the companies can set their own prices, but will not have to pay royalties to Gilead until the World Health Organization declares an end to the public health emergency for the novel coronavirus, or until another medicine or vaccine is approved to treat or prevent Covid-19.


The promise and limitations of remdesivir, the first drug to prove capable of helping to fight Covid-19, have kicked off efforts to see if it can work better in combination with other treatments and to create new, easier methods of administering it, The Wall Street Journal writes. Six Covid-19 drug trials currently under way specify testing remdesivir with another medicine. Another five trials are of drugs that would be given in tandem with whatever a hospital uses as standard treatment — which increasingly means remdesivir.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!